Skip to main
CLOV

CLOV Stock Forecast & Price Target

CLOV Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Clover Health Investments is well-positioned for continued financial performance. With strong retention in geographies with CA adoption, the company's 95%+ retention for 2026 bodes well for continued medical cost performance. The company's CA-powered physicians have seen better health outcomes and lower costs, leading to a 8% MCR differential compared to physicians who do not use CA. Additionally, the company's growth in markets with high CA adoption and strong member retention means there will be a strong base of members being seen by physicians powered by CA, which is expected to drive profitability in 2027.

Bears say

Clover Health Investments is facing potential headwinds due to regulatory changes and increased competition in the Medicare Advantage market. Its unique care model, Clover Assist, may experience volatility in managing medical expense trends. The company also faces liquidity risks, which could result in dilutive equity financing. While its recent membership growth and profitability expectations for 2026 are positive, concerns remain about the sustainability of this growth and overall profitability.

CLOV has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Clover Health Investments (CLOV) Forecast

Analysts have given CLOV a Buy based on their latest research and market trends.

According to 3 analysts, CLOV has a Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Clover Health Investments (CLOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.